Zoetis Inc. (NYSE:ZTS) Shares Sold by Moseley Investment Management Inc.

Moseley Investment Management Inc. decreased its position in Zoetis Inc. (NYSE:ZTS) by 23.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,642 shares of the company’s stock after selling 1,767 shares during the period. Moseley Investment Management Inc.’s holdings in Zoetis were worth $919,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. Cherry Creek Investment Advisors Inc. increased its holdings in Zoetis by 2.0% in the 3rd quarter. Cherry Creek Investment Advisors Inc. now owns 3,021 shares of the company’s stock worth $590,000 after acquiring an additional 58 shares in the last quarter. Grove Bank & Trust raised its position in shares of Zoetis by 0.5% during the 3rd quarter. Grove Bank & Trust now owns 11,763 shares of the company’s stock worth $2,298,000 after purchasing an additional 61 shares during the last quarter. Hancock Whitney Corp lifted its stake in Zoetis by 0.3% in the 3rd quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock valued at $3,628,000 after buying an additional 61 shares in the last quarter. Strategy Asset Managers LLC boosted its holdings in Zoetis by 3.5% in the 3rd quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock worth $356,000 after buying an additional 62 shares during the last quarter. Finally, Edge Capital Group LLC increased its stake in Zoetis by 3.7% during the 2nd quarter. Edge Capital Group LLC now owns 1,786 shares of the company’s stock worth $310,000 after buying an additional 64 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

Zoetis stock opened at $164.31 on Wednesday. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The company has a 50-day moving average price of $171.31 and a 200 day moving average price of $180.16. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.53. The stock has a market cap of $74.13 billion, a P/E ratio of 30.89, a PEG ratio of 2.91 and a beta of 0.89.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.46 by $0.12. The business had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. During the same quarter in the prior year, the company posted $1.36 EPS. The business’s revenue for the quarter was up 11.6% on a year-over-year basis. Sell-side analysts anticipate that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.22%. The ex-dividend date is Tuesday, January 21st. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. Zoetis’s dividend payout ratio is 37.59%.

Analyst Ratings Changes

ZTS has been the subject of several research reports. JPMorgan Chase & Co. boosted their price target on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. UBS Group began coverage on shares of Zoetis in a research note on Monday, December 9th. They set a “neutral” rating and a $196.00 target price on the stock. Stifel Nicolaus reduced their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Leerink Partners assumed coverage on shares of Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target on the stock. Finally, Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. One analyst has rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $211.89.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.